PHVS

PHVS

Pharvaris BV

Rev —top 1%5Y
Hold

Pharvaris BV develops oral therapies for rare diseases, focusing on bradykinin-mediated conditions like hereditary angioedema and acquired angioedema. Its main candidate, deucrictibant, is a B2-receptor antagonist in late-stage clinical trials.

⚕️ Healthcare NASDAQ Listed 2021 € EUR
$1,000 invested 5 years ago $2,142today

Score Overview

1 Year
Score
Net Growth3.70%
Net TrendGrew
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-295.98%
Net Trend20%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-295.98%
Net Trend20%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Pharvaris BV fundamental performance

Across Pharvaris BV's full reported history, from 2021 to 2025, revenue held from € 0.00 to € 0.00 and net income went from -€ 42M to -€ 175M. Revenue increased in 0% of the years measured; net income in 20%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 36.46
1 Year2025-08-12
$ 21.0972.88%
5 Years2021-08-12
$ 17.02114.22%
All Time2021-02-05
$ 29.0025.72%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026€ 0.00-€ 169M€ 246M
2025€ 0.00-€ 175M€ 291M
2024€ 0.00-€ 134M€ 280M
2023€ 0.00-€ 100M€ 391M
2022€ 0.00-€ 76M€ 161M
IPO2021€ 0.00-€ 42M€ 209M

Explore beyond PHVS

You're looking at Pharvaris BV. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies